Kymera Therapeutics Inc’s recently made public that its Chief Legal Officer Chiniara Ellen unloaded Company’s shares for reported $0.13 million on Jan 06 ’25. In the deal valued at $41.75 per share,3,129 shares were sold. As a result of this transaction, Chiniara Ellen now holds 54,826 shares worth roughly $2.19 million.
Then, Chiniara Ellen bought 3,129 shares, generating $130,135 in total proceeds.
Before that, Esposito Pamela sold 2,500 shares. Kymera Therapeutics Inc shares valued at $122,500 were divested by the Director at a price of $49.00 per share. As a result of the transaction, Esposito Pamela now holds 0 shares, worth roughly $0.0.
BTIG Research initiated its Kymera Therapeutics Inc [KYMR] rating to a Buy in a research note published on December 10, 2024; the price target was $60. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”a Market perform”‘ rating. Wells Fargo also remained covering KYMR and has increased its forecast on December 02, 2024 with a “an Overweight” recommendation from previously “an Equal weight” rating. Stephens started covering the stock on November 18, 2024. It rated KYMR as “an Overweight”.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -4.06% to $39.90. Over the last five days, the stock has lost -0.52%. Kymera Therapeutics Inc shares have fallen nearly -0.82% since the year began. Nevertheless, the stocks have risen 46.58% over the past one year. While a 52-week high of $53.27 was reached on 01/06/25, a 52-week low of $22.35 was recorded on 01/02/25. SMA at 50 days reached $44.84, while 200 days put it at $41.31.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 38.76, which if violated will result in even more drops to 37.62. On the upside, there is a resistance level at 42.14. A further resistance level may holdings at 44.37. The Relative Strength Index (RSI) on the 14-day chart is 41.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.31%. Stochastics %K at 50.33% indicates the stock is a holding.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2024-12-13, dropping by -0.33 million shares to a total of 8.79 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 9.12 million shares. There was a decline of -3.74%, which implies that there is a negative sentiment for the stock.
